Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Invasive Carcinoma with Medullary Features

Living reference work entry

Latest version View entry history

DOI: https://doi.org/10.1007/978-3-319-28845-1_4714-2

Synonyms

Definition

The WHO Classification of Tumors of the Breast recommends the use of the collective term “Carcinoma with Medullary Features” to encompass tumors previously diagnosed as classical medullary carcinoma (classical MC), atypical medullary carcinoma (atypical MC), and a subgroup of invasive breast carcinoma of no special type (NST) with medullary characteristics (Lakhani et al. 2012).

These tumors are characterized by the following histological features:
  1. 1.

    An expansile or pushing border

     
  2. 2.

    A syncytial growth pattern

     
  3. 3.

    High cytonuclear grade

     
  4. 4.

    A prominent lymphoplasmacytic infiltrate

     

These diagnostic criteria are less strict than the original criteria proposed by Ridolfi et al. for a diagnosis of classical MC which requires complete circumscription, a...

This is a preview of subscription content, log in to check access

References and Further Reading

  1. Badve, S., Dabbs, D., Schnitt, S., Baehner, F., Decker, T., Eusebi, V., et al. (2010). Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology, 24, 157–167.CrossRefGoogle Scholar
  2. Bertucci, F., Finetti, P., Cervera, N., Charafe-Jauffret, E., Mamessier, E., Adélaïde, J., et al. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Research, 66, 4636–4644.CrossRefGoogle Scholar
  3. Dua, I., & Tan, A. R. (2017). Immunotherapy for triple-negative breast cancer: A focus on immune checkpoint inhibitors. American Journal of Haematology and Oncology, 13, 20–27.Google Scholar
  4. Eisinger, F., Noguès, C., Birnbaum, D., Jacquemier, J., & Sobol, H. (1998). BRCA1 and medullary breast cancer. Journal of the American Medical Association, 280, 1227–1228.CrossRefGoogle Scholar
  5. Ellis, I. O., Al-Sam, S., Anderson, N., Carder, P., Deb, R., Girling, A., et al. (2016). Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. (2016). Rcpath.org. Available from: http://www.rcpath.org. Accessed Sept 2017.
  6. Flucke, U., Flucke, M., Hoy, L., Breuer, E., Goebbels, R., Rhiem, K., et al. (2010). Distinguishing medullary carcinoma of the breast from high-grade hormone receptor-negative invasive ductal carcinoma: An immunohistochemical approach. Histopathology, 56, 852–859.CrossRefGoogle Scholar
  7. Hicks, D. G., & Lester, S. C. (2017). Carcinoma with medullary features. Available from: https://app.expertpath.com. Accessed Sept 2014.
  8. Huober, J., Gelber, S., Coates, A. S., Viale, G., Ohlschlegel, C., et al. (2012). Prognosis of medullary breast cancer: Analyses of 13 international breast cancer study group (IBCSG) trials. Journal of Clinical Oncology, 11, 2843–2851.Google Scholar
  9. Jacquemier, J., Padovani, L., Rabayrol, L., Lakhani, S., Penault-Llorca, F., Denoux, Y., et al. (2005). Typical medullary breast carcinomas have a basal/myoepithelial phenotype. The Journal of Pathology, 207, 260–268.CrossRefGoogle Scholar
  10. Lakhani, S., Ellis, I. O., Schnitt, S. J., Tan, P. H., & van de Vijver, M. J. (2012). WHO classification of tumours of the breast (pp. 46–47). Lyon: International Agency for Research on Cancer.Google Scholar
  11. Lehmann, B., & Pietenpol, J. (2013). Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. The Journal of Pathology, 232, 142–150.CrossRefGoogle Scholar
  12. Mateo, A., Pezzi, T., Sundermeyer, M., Kelley, C., Klimberg, V., & Pezzi, C. (2016). Chemotherapy significantly improves survival for patients with T1c-T2N0M0 medullary breast cancer: 3739 cases from the National Cancer Data Base. Annals of Surgical Oncology, 24, 1050–1056.CrossRefGoogle Scholar
  13. Matkovic, B., Juretic, A., Separovic, V., Novosel, I., Separovic, R., Gamulin, M., et al. (2008). Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p 63 and EGFR antigen expression in medullary breast cancer. Tumori, 94, 838–844.CrossRefGoogle Scholar
  14. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumors. Nature, 406, 474–452.CrossRefGoogle Scholar
  15. Rakha, E., & Green, A. (2017). Molecular classification of breast cancer: What the pathologist needs to know. Pathology, 49, 111–119.CrossRefGoogle Scholar
  16. Ridolfi, R., Rosen, P., Port, A., Kinne, D., & Miké, V. (1977). Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer, 40, 1365–1385.CrossRefGoogle Scholar
  17. Silwal-Pandit, L., Vollan, H., Chin, S., Rueda, O., McKinney, S., Osako, T., et al. (2014). TP53 mutation Spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clinical Cancer Research, 20, 3569–3580.CrossRefGoogle Scholar
  18. Stanton, S., & Disis, M. (2016). Clinical significance of tumor-infiltrating lymphocytes in breast cancer. Journal for Immunotherapy of Cancer, 4, 59.CrossRefGoogle Scholar
  19. Tung, N., Garber, J., Hacker, M., Torous, V., Freeman, G., Poles, E., et al. (2016). Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. Breast Cancer, 2, 16002.PubMedPubMedCentralGoogle Scholar
  20. Vincent-Salomon, A., Gruel, N., Lucchesi, C., MacGrogan, G., Dendale, R., Sigal-Zafrani, B., et al. (2007). Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Research, 9, R24.CrossRefGoogle Scholar
  21. Weigelt, B., Geyer, F., & Reis-Filho, J. (2010). Histological types of breast cancer: How special are they? Molecular Oncology, 4, 192–208.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HistopathologyIrish National Breast Screening Programme and St. Vincent’s University HospitalDublin 4Ireland
  2. 2.School of MedicineUniversity College DublinDublinIreland